ABSTRACT
Background Understanding COVID-19’s impact on children is vital for public health policy, yet age-specific data is scarce, especially in Uganda. This study examines SARS-CoV-2 seroprevalence and risk factors among Ugandan children at two timepoints, along with COVID-19-related knowledge and practices in households, including adult vaccination status.
Methods Baseline surveys were conducted in 12 communities from April to May 2021 (post-Alpha wave) and follow-up surveys in 32 communities from November 2021 to March 2022 (Omicron wave). Household questionnaires and blood samples were collected to test for malaria by microscopy and for SARS-CoV-2 using a Luminex assay. Seroprevalence was estimated at both the survey and community level. Mixed-effects logistic regression models assessed the association between individual and household factors and SARS-CoV-2 seropositivity in children, adjusting for household clustering.
Results More households reported disruptions in daily life at baseline compared to follow-up, though economic impacts lingered. By the follow-up survey, 52.7% of adults had received at least one COVID-19 vaccine dose. Overall seroprevalence in children was higher at follow-up compared to baseline (71.6% versus 19.2%, p < 0.001). Seroprevalence in children ranged across communities from 6-37% at baseline and 50-90% at follow-up. At baseline, children from the poorest households were more likely to be infected. Increasing age remained the only consistent risk factor for SARS-CoV-2 seroconversion at both timepoints.
Conclusions Results indicate that a larger number of children were infected by the Delta and Omicron waves of COVID-19 compared to the Alpha wave. This study is the largest seroprevalence survey in children in Uganda, providing evidence that most children were infected with SARS-CoV-2 before the vaccine was widely available to pediatric populations. Pediatric infections were vastly underreported by case counts, highlighting the importance of seroprevalence surveys in assessing disease burden when testing and reporting rates are limited and many cases are mild or asymptomatic.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding We acknowledge sources of funding support including Makerere University Research and Innovations Fund (MAKRIF/DVCFA/026/20) (IB, JFN, JN, MK, PN, IN); Fogarty International Center of the National Institutes of Health (D43TW010526) (IB, JFN, GC, PN, TK, SG, MN, Dr. ST); the Bill and Melinda Gates Foundation, INV-
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All methods were carried out in accordance with relevant guidelines and regulations including the Declaration of Helsinki. Study procedures were approved by Institutional Review Boards (IRBs) at Makerere University School of Medicine Research and Ethics Committee (SOMREC), the Uganda National Council for Science and Technology (UNCST), the University of California San Francisco and London School of Hygiene and Tropical Medicine. A request for waiver of consent to conduct laboratory analysis was obtained from SOMREC. Furthermore, informed consent was obtained from all subjects in this manuscript as stated in the methods (lines 124-125).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* co-first authors
Errors noted in the abstract (timing of first round) and in the Figure 1/ Figure 2 references in the methods.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
